One mechanism of resistance to trastuzumab in human epidermal growth factor receptor-2 (HER2)-positive breast cancer (BC) is increased epidermal growth factor receptor (EGFR) expression. We have developed 111 In-labeled bispecific radioimmunoconjugates (bsRICs) that bind HER2 and EGFR on BC cells by linking trastuzumab Fab fragments through a polyethylene glycol (PEG 24 ) spacer to epidermal growth factor (EGF). We hypothesized that tumors coexpressing HER2 and EGFR could be treated by dualreceptor-targeted radioimmunotherapy with these bsRICs labeled with the β-particle emitter 177 In-labeled trastuzumab Fab or EGF killed tumor cells that predominantly expressed HER2 or EGFR, respectively, whereas bsRICs were cytotoxic to cells that displayed either HER2 or EGFR or both receptors. bsRICs were more effective than monospecific agents. 177 Lu-DOTA-Fab-PEG 24 -EGF was more cytotoxic than 111 In-DTPAFab-PEG 24 -EGF. The tumor uptake of 177 Lu-DOTA-Fab-PEG 24 -EGF was 2-fold greater than 177 Lu-DOTA-trastuzumab Fab or 177 Lu-DOTA-EGF. The NOAEL for 177 Lu-DOTA-Fab-PEG 24 -EGF was 11.1 MBq (10 μg).
Over expression of the human epidermal growth factor receptor-2 (HER2) occurs in about 20%-25% of breast cancers (BCs) (1) and is the therapeutic target for trastuzumab (Herceptin; Roche Pharmaceuticals), pertuzumab (Perjeta), and trastuzumab-emtansine (T-DM1; Kadcycla) (2) . Although these HER2-targeted therapies combined with chemotherapy have improved the outcome for women with HER2-positive metastatic BC, not all patients respond and many patients with HER2-positive BC develop resistance within a year (3) . Pertuzumab combined with trastuzumab and docetaxel has improved patient survival compared with trastuzumab and docetaxel alone (4) . Trastuzumab combined with the HER2 tyrosine kinase inhibitor lapatinib improved survival in patients with progressive HER2-positive BC (5) . Recently, T-DM1 has been shown to be more effective than lapatinib combined with capecitabine for treatment of BC resistant to trastuzumab and taxanes (6) . Despite these encouraging results, trastuzumab resistance remains a challenge. The reasons for tumor resistance are not completely understood but one mechanism is the upregulation of other human epidermal growth factor receptor (EGFR) family members (e.g., EGFR and HER3) (7) (8) (9) . Our group has developed 111 In-labeled bispecific radioimmunoconjugates (bsRICs) that recognize EGFR or HER3 expressed alone or coexpressed with HER2 on BC cells (10, 11) . These bsRICs may be useful for molecular imaging or radioimmunotherapy of trastuzumab-resistant tumors that coexpress these receptors. These bsRICs were constructed by linking trastuzumab Fab fragments that bind HER2 through a 24-mer polyethylene glycol (PEG 24 ) spacer to human epidermal growth factor (EGF) or to heregulin-b, which are the natural ligands for EGFR and HER3, respectively. Micro-SPECT/CT imaging demonstrated specific accumulation of these bsRICs in tumor xenografts in mice that displayed HER2 or EGFR or HER3 or HER2 coexpressed with EGFR or HER3 (10, 11) .
Our hypothesis in the current study was that 177 Lu-or 111 Inlabeled bsRICs that bind HER2 and EGFR would cause cytotoxicity in vitro to BC cells expressing these receptors and tumor growth inhibition in vivo in athymic mice bearing trastuzumab-sensitive or -resistant BC xenografts coexpressing HER2 and EGFR. 177 (12) . 111 In-labeled trastuzumab modified with nuclear translocation sequence (NLS) peptides ( 111 In-NLS-trastuzumab) to promote its nuclear importation after internalization was highly effective for killing HER2-positive BC cells in vitro (13) and strongly inhibited tumor growth in vivo in athymic mice bearing human HER2-overexpressing BC xenografts (14) .
MATERIALS AND METHODS

Cancer Cells
SK-OV-3 human ovarian cancer cells and MDA-MB-231 human BC cells were purchased from the American Type Culture Collection. The MDA-MB-231/H2N cell line was derived from EGFR-positive MDA-MB-231 cells that were stably transfected to overexpress c-erbB-2 (HER2) (15) . TrR1 cells are a subclone of MDA-MB-231/H2N cells with acquired trastuzumab resistance but that continue to express HER2 (15) . Both MDA-MB-231/H2N and TrR1 cells were provided by Dr. Robert S. Kerbel (Sunnybrook Health Sciences Centre). SK-OV-3 cells were cultured in RPMI-1640 medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum (Invitrogen). MDA-MB-231, MDA-MB-231/H2N, and TrR1 cells were cultured in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum. All cells were cultured in 5% CO 2 at 37°C. BC cells were selected on the basis of their reported HER2 or EGFR expression (11, 16, 17) , but these receptor densities were confirmed by direct (saturation) radioligand binding assays with 111 In-labeled trastuzumab Fab fragments or 111 In-labeled EGF. Because MDA-MB-231 cells exhibited low HER2 expression (5.4 · 10 4 receptors/cell) and moderate EGFR density (5.2 · 10 5 receptors/cell), these cells were designated as HER2 low /EGFR mod . MDA-MB-231/H2N cells exhibited moderate HER2 and EGFR expression (4.5 · 10 5 and 4.8 · 10 5 receptors/cell, respectively) and were designated as HER2 mod /EGFR mod . TrR1 cells displayed 4.4 · 10 5 HER2/cell and 4.6 · 10 5 EGFR/cell and were designated as HER2 mod /EGFR mod . SK-OV-3 cells exhibited high HER2 but low EGFR expression (9.6 · 10 5 and 8 · 10 4 receptors/cell, respectively) (18) and were designated as HER2 high /EGFR low . The HER2 and EGFR density measured by radioligand binding assays in these cells was in agreement with the receptor expression assessed by Western blot (15, 19) .
bsRICs Fab-PEG 24 -EGF bispecific immunoconjugates (bsICs) recognizing HER2 and EGFR were constructed as reported by cross-linking trastuzumab Fab fragments (molecular weight, 50 kDa) produced by proteolytic digestion of trastuzumab IgG to human EGF (molecular weight, 6.2 kDa; Peprotech) through a PEG 24 spacer (11) . Insertion of this PEG 24 spacer improved the binding of analogous 111 In-diethylenetriaminepentaacetic acid (DTPA)-trastuzumab Fab-heregulin bsRICs to HER2 and HER3 on BC cells (10) and preserved the HER2 and EGFR binding of 111 In-DTPA-trastuzumab-PEG 24 -EGF bsRICs (11) . The bsICs were reconcentrated to 1.0 mg/mL in phosphate-buffered saline (pH 7.0) on a Microcon centrifugal device (molecular weight cut-off, 30 kDa; Millipore) and then derivatized with a 10-fold molar excess of DOTA-N-hydroxysuccinimide ester (NHS-DOTA; Macrocyclics Inc.) for labeling with 177 Lu. DOTA conjugation efficiency was measured by analysis of a sample of the unpurified reaction mixture tracelabeled with 177 Lu by instant thin-layer silica gel chromatography (Pall Life Sciences) developed in 100 mM sodium citrate (pH 5.0). The conjugation efficiency was multiplied by the 10-fold molar excess of DOTA in the reaction to determine the number of DOTA chelators per molecule of bsICs. The bsICs were purified on a Sephadex G25 (SigmaAldrich) minicolumn eluted with 400 mM ammonium acetate buffer, pH 5.0, to remove unconjugated DOTA. Purified DOTA-Fab-PEG 24 -EGF (200 mg; 100 mL) was labeled by incubation with 20 MBq (5 mL) of 177 LuCl 3 (PerkinElmer) for 90 min at 42°C. 111 In-DTPA-Fab-PEG 24 -EGF bsRICs were synthesized as reported (11) . 111 In-DTPA-trastuzumab Fab, 177 Lu-DOTA-trastuzumab Fab, 111 In-DTPA-EGF, and 177 Lu-DOTA-EGF were synthesized for comparison. There were 0.8 6 0.3 DTPA or 0.7 6 0.4 DOTA chelators per molecule of EGF, respectively. Fab fragments were derivatized with 2.3 6 0.5 DOTA or 3.6 6 0.7 DTPA per molecule. The final radiochemical purity of all radioimmunoconjugates was greater than 90% measured by instant thin-layer silica gel chromatography.
The HER2 and EGFR binding of 177 Lu-labeled bsRICs was evaluated by competition radioligand binding assays using SK-OV-3 (HER2 high /EGFR low ), MDA-MB-231 (HER2 low /EGFR mod ), or MDA-MB-231/H2N (HER2 mod /EGFR mod ) cells. Approximately 1.5 · 10 5 cells were seeded into 24-well plates and cultured overnight. The cells were then exposed to 10 nM (1.0 MBq/mg) of 177 Lu-DOTA-Fab-PEG 24 -EGF in phosphate-buffered saline in the presence of 500 nM of unlabeled Fab, EGF, or both competitors. After incubation for 3 h at 4°C, unbound radioactivity was removed and the cells were solubilized in 1 N NaOH and transferred to g-counting tubes, and the cell bound radioactivity was measured in a g-counter. The binding of 177 Lu-DOTA-trastuzumab Fab or 177 Lu-DOTA-EGF to MDA-MB-231 cells (HER2 low /EGFR mod ) or MDA-MB-231/H2N cells (HER2 mod /EGFR mod ) was determined in the presence or absence of an excess of trastuzumab Fab (69 nmol/L) or EGF (1,659 nmol/L). The HER2-and EGFR-binding properties of 111 In-labeled bsRICs, 111 In-DTPAtrastuzumab Fab, or 111 In-DTPA-EGF were previously reported (11) .
Clonogenic Survival (CS) Assays
The CS of SK-OV-3 (HER2 high /EGFR low ), MDA-MB-231 (HER2 low / EGFR mod ), MDA-MB-231/H2N (HER2 mod /EGFR mod ), or trastuzumabresistant TrR1 (HER2 mod /EGFR mod ) cells exposed to 177 Lu-DOTA-Fab-PEG 24 -EGF (350 6 14.3 MBq/mg), 177 Lu-DOTA-trastuzumab Fab (350 6 9.4 MBq/mg), or 177 Lu-DOTA-EGF (350 6 13.5 MBq/mg) was determined. Approximately 1.5 · 10 5 cells were seeded into 24-well plates and cultured overnight. The cells were then exposed for 24 h at 37°C to 500 mL of serum-free growth medium containing 2.5 · 10 27 mol/L of 177 Lu-DOTA-Fab-PEG 24 -EGF, 177 Lu-DOTA-trastuzumab Fab, or 177 Lu-DOTA-EGF. Controls consisted of cells exposed to growth medium alone or cells exposed to equivalent concentrations of unlabeled Fab-PEG 24 -EGF, trastuzumab Fab, or EGF. For comparison, the CS was evaluated in these cells exposed to the same concentrations of 111 In-DTPA-trastuzumab Fab (350 6 19.4 MBq/mg), 111 In-DTPA-EGF (349 6 15.2 MBq/mg), or 111 In-DTPA-Fab-PEG 24 -EGF (350 6 12.8 MBq/mg). After treatment, the cells were recovered by trypsinization and rinsed twice with medium, and sufficient cells were seeded in triplicate into 6-well plates to obtain a measurable number of colonies after culturing for 5 d. Surviving colonies were stained with methylene blue, and those with 30 cells or more were counted. The plating efficiency was determined by dividing the number of colonies formed by the number of cells seeded. The CS was calculated by dividing the plating efficiency for treated cells by that for untreated cells.
Biodistribution Studies
The tumor and normal tissue biodistribution of the 177 Lu-DOTA-PEG 24 -EGF bsRICs was compared with 177 Lu-DOTA-trastuzumab Fab or 177 Lu-DOTA-EGF in female athymic CD1 nu/nu mice (Charles River) bearing subcutaneous MDA-MB-231/H2N (HER2 mod /EGFR mod ) BC xenografts at 48 h after injection. This time point was selected on the basis of an earlier study that evaluated the biodistribution of 111 In-DTPA-Fab-PEG 24 -EGF from 4 to 72 h after injection in mice with MDA-MB-231//H2N tumors and determined that maximum tumor uptake occurred at 48 h after injection (11) . Mice were inoculated subcutaneously in the thigh with 1 · 10 7 cells in 200 mL of a 1:1 mixture of Matrigel (BD Biosciences) and serum-free growth medium. After 4-6 wk, groups of 3 tumor-bearing mice were injected intravenously (tail vein) with 177 Lu-DOTA-Fab-PEG 24 -EGF, 177 Lu-DOTA-trastuzumab Fab, or 177 Lu-DOTA-EGF (10 mg, 3-5 MBq per mouse) in 100 mL of normal saline. Mice were sacrificed, and the tumor and samples of selected normal tissues including blood were collected and weighed and their radioactivity measured in a g-counter. Tumor and normal tissue uptake were expressed as percentage injected dose per gram (%ID/g). All animal studies were conducted under a protocol (no. 989.13) approved by the Animal Care Committee at the University Health Network in accordance with guidelines of the Canadian Council on Animal Care.
Radiation Dosimetry Estimates
The radiation-absorbed doses to the tumor and normal tissues in CD1 athymic nu/nu mice with subcutaneous MDA-MB-231/H2N xenografts after injection of 111 In-DTPA-Fab-PEG 24 -EGF or 177 Lu-DOTA-Fab-PEG 24 -EGF were estimated on the basis of the reported biodistribution of 111 In-DTPA-PEG 24 -EGF (11) in this same tumor xenograft mouse model, assuming that these 2 analogous bsRICs would exhibit comparable tumor and normal tissue uptake. The cumulative radioactivity in source organs was calculated and the absorbed doses estimated using published S values for mice (20) and OLINDA/EXT radiation dose assessment software, as described in the supplemental information (supplemental materials are available at http://jnm.snmjournals.org) (21) .
Normal-Tissue Toxicity Studies
Groups of 5 female non-tumor-bearing BALB/c mice were injected intravenously (tail vein) with 3.7, 11.1, or 18.5 MBq of 177 Lu-DOTAFab-PEG 24 -EGF (10 mg, 100 mL). Control mice received injections of normal saline. Body weight was monitored every 2-4 d for 14 d. The mice were then sacrificed by cervical dislocation under anesthesia and samples of blood collected into ethylenediaminetetraacetic acidcoated microtubes for biochemistry (serum alanine aminotransferase [ALT] and creatinine [Cr] ) and hematology analyses. A complete blood cell count as well as hematocrit and hemoglobin were measured on a HemaVet 950FS (Drew Scientific) instrument.
Radioimmunotherapy Studies
The tumor growth-inhibitory properties of 177 Lu-DOTA-Fab-PEG 24 -EGF and 111 In-DTPA-Fab-PEG 24 -EGF were compared in groups of 5 female athymic CD1 nu/nu mice implanted subcutaneously with trastuzumab-sensitive MDA-MB-231/H2N (HER2 mod / EGFR mod ) or trastuzumab-resistant TrR1 (HER2 mod /EGFR mod ) xenografts. Mice bearing 2-to 5-mm-diameter tumors received a single intraperitoneal injection of 11.1 MBq (10 mg) of 177 Lu-DOTA-Fab-PEG 24 -EGF or 111 In-DTPA-Fab-PEG 24 -EGF. Control mice received an intraperitoneal injection of unlabeled DOTA-Fab-PEG 24 -EGF (10 mg) or normal saline. We have previously found that 111 In-labeled monoclonal antibodies are rapidly absorbed after intraperitoneal injection, with an absorption half-life of 1.9 h that provides a bioavailability of 70% compared with intravenous injection (14) . Others have similarly found equivalent blood concentrations at 24 h after intraperitoneal or intravenous injection of radiolabeled antibodies (22) . The tumor length and width were measured using calipers. The tumor volume was calculated as (length · width 2 ) multiplied by 0.5, and the tumor growth index (TGI) was calculated by dividing the tumor volume at each time point by the initial tumor volume. The mean TGI was plotted versus the time from the start of treatment to obtain the tumor growth curves. Treatment experiments were terminated when tumor size exceeded a mean diameter of 12 mm or at the planned end of the study (49 d).
Statistical Analysis
Statistical comparisons were made using a 2-tailed Student t test (P , 0.05).
RESULTS bsRICs
The synthesis and characterization of 111 In-DTPA-Fab-PEG 24 -EGF bsRICs were previously reported (11) . 177 Lu-DOTA-Fab-PEG 24 -EGF bsRICs were constructed by conjugating trastuzumab Fab fragments modified with NHS-PEG 24 -maleimide to EGF functionalized with 2-iminothiolane (Traut reagent) and then derivatizing these bsICs with NHS-DOTA for labeling with 177 Lu (Supplemental Fig. 1 ). There were 3.2 6 0.8 DOTA chelators substituted per molecule of bsICs. The binding of 177 Lu-DOTA-Fab-PEG 24 -EGF to SK-OV-3 cells (HER2 high /EGFR low ) was reduced to 12.4% 6 2.6%, 105.0% 6 10.7%, and 10.1% 6 1.6% by coincubation with a 100-fold molar excess of trastuzumab Fab, EGF, or both ligands, respectively, compared with no competition (Fig. 1A) . The binding of 177 Lu-DOTA-Fab-PEG 24 -EGF to MDA-MB-231 cells (HER2 low /EGFR mod ) was reduced to 95.2% 6 7.5%, 20.3% 6 2.8%, and 9.9% 6 2.9% by trastuzumab Fab, EGF, or both ligands, respectively (Fig. 1B) . The binding to MDA-MB-231/ H2N cells (HER2 mod /EGFR mod ) was reduced to 52.7% 6 2.8%, 65.6% 6 2.3%, and 4.4% 6 0.9%, respectively, by competition with trastuzumab Fab, EGF, or both ligands (Fig. 1C ). An excess of unlabeled trastuzumab Fab inhibited the binding of 177 Lu-DOTA-Fab to MDA-MB-231/H2N cells (HER2 mod /EGFR mod ) but not to MDA-MB-231 cells (HER2 low /EGFR mod ) whereas an excess of unlabeled EGF inhibited the binding of 177 Lu-DOTA-EGF to both cell lines (Supplemental Fig. 2 ).
Clonogenic Survival (CS)
There was no effect on the CS of MDA-MB-231 (HER2 low /EGFR mod ) cells exposed for 24 h to 2.5 · 10 27 mol/L of unlabeled trastuzumab Fab, EGF, or Fab-PEG 24 -EGF compared with untreated cells (Fig. 2A) . No significant decrease in survival was found for MDA-MB-231 cells treated with 111 In-DTPA-trastuzumab Fab (CS, 94.5% 6 10.1%), but the survival of MDA-MB-231 cells exposed to 111 In-DTPA-EGF was reduced by 2-fold (CS, 55.8% 6 3.0%; P , 0.01) compared with untreated cells. The survival of MDA-MB-231 cells treated with 111 In-DTPA-Fab-PEG 24 -EGF was decreased by 1.4-fold compared with untreated cells, but this difference was not significant (CS, 70.1% 6 15.7% vs. 100.0% 6 19.7%; P 5 0.09). The survival of MDA-MB-231 cells was significantly decreased by 2.6-to 3.3-fold by 177 Lu-DOTA-EGF or 177 Lu-DOTA-Fab-PEG 24 -EGF (CS, 38.4% 6 9.0%, P , 0.0001; and 30.2% 6 4.8%, P , 0.0001, respectively; Fig. 2A ). There was no significant effect of 177 Lu-DOTA-trastuzumab Fab on the CS of MDA-MB-231 cells (77.3% 6 19.2%; P 5 0.06).
The survival of SK-OV-3 (HER2 high / EGFR low ) cells exposed to unlabeled trastuzumab Fab or Fab-PEG 24 -EGF was significantly decreased compared with untreated cells (71.9% 6 9.0%, P 5 0.02; and 71.8% 6 2.2%, P 5 0.01, respectively, vs. 100.0% 6 10.5%; Fig. 2B ). Unlabeled EGF had no effect on the CS of these cells (94.4% 6 4.5%). The survival of SK-OV-3 cells treated with 111 In-DTPAtrastuzumab Fab or 111 In-DTPA-Fab-PEG 24 -EGF was decreased compared with untreated cells (CS, 65.9% 6 7.0%, P 5 0.01; and 59.8% 6 4.3%, P 5 0.003, respectively). The survival of SK-OV-3 cells treated with 111 In-DTPA-EGF was significantly decreased (CS, 75.5% 6 7.5%; P 5 0.02) compared with untreated cells. 177 Lu-DOTA-trastuzumab Fab and 177 Lu-DOTA-Fab-PEG 24 -EGF killed SK-OV-3 cells more efficiently than the corresponding 111 In-labeled agents (CS, 35.5% 6 7.5% and 19.8% 6 4.2%, respectively; P , 0.001). 177 Lu-DOTA-EGF significantly reduced the CS of SK-OV-3 cells to 65.5% 6 7.5% (P , 0.01).
The survival of MDA-MB-231/H2N cells (HER2 mod /EGFR mod ) was significantly reduced to 71.6% 6 5.6% by treatment with unlabeled trastuzumab Fab for 24 h (P 5 0.01; Fig. 2C ) but not by unlabeled EGF (79.1% 6 8.5%; P 5 0.054) or Fab-PEG 24 -EGF (86.4% 6 8.0%; P 5 0.14). There was no effect of unlabeled trastuzumab Fab, EGF, or Fab-PEG 24 -EGF on the CS of TrR1 (HER2 mod /EGFR mod ) cells (Fig. 2D) . TrR1 cells treated with 111 In-DTPA-trastuzumab Fab and 111 In-DTPA-EGF also showed no significant decrease in survival (CS, 92.6% 6 17.6%, P 5 0.6; and 88.6% 6 0.6%, P 5 0.09, respectively). However, exposure to 111 In-DTPAFab-PEG 24 -EGF decreased the CS of these cells to 67.4% 6 11.9% (P 5 0.01). Treatment of TrR1 cells with 177 Lu-DOTAtrastuzumab Fab, 177 Lu-DOTA-EGF, or 177 Lu-DOTA-Fab-PEG 24 -EGF significantly reduced their CS to 51.7% 6 9.8% (P 5 0.003), 41.5% 6 8.3% (P 5 0.001), and 20.3% 6 5.6% (P , 0.001), respectively. 177 Lu-DOTA-trastuzumab Fab, 177 Lu-DOTA-EGF, and 177 Lu-DOTA-Fab-PEG 24 -EGF were more cytotoxic than the corresponding 111 In-labeled agents.
Biodistribution Studies
Tumor uptake at 48 h after injection in mice bearing subcutaneous MDA-MB-231/ H2N (HER2 mod /EGFR mod ) BC xenografts was 2.3-fold significantly greater for 177 Lu-DOTA-Fab-PEG 24 -EGF (7.3 6 1.5 %ID/g) than 177 Lu-DOTA-trastuzumab Fab (3.2 6 1.5 %ID/g; P 5 0.02) and 3.5-fold significantly higher than 177 Lu-DOTA-EGF (2.1 6 0.7 %ID/g; P , 0.01; Fig. 3 ). The blood concentration of radioactivity for 177 Lu-DOTA-Fab-PEG 24 -EGF (1.2 6 0.1 %ID/g) was 4-fold significantly higher than 177 Lu-DOTA-EGF (0.3 6 0.3 %ID/g; P , 0.01) but not greater than 177 Lu-DOTA-trastuzumab Fab (1.0 6 0.1 %ID/g; P 5 0.07). Similar results were found for the heart. Spleen uptake of 177 Lu-DOTAFab-PEG 24 -EGF (4.0 6 1.8 %ID/g) was 2.8-fold significantly greater than 177 Lu-DOTA-trastuzumab Fab (1.4 6 0.1 %ID/g; P 5 0.01) and 2.2-fold higher than 177 Lu-DOTA-EGF (1.8 6 0.2 %ID/g; P 5 0.02). Liver uptake was 2.6-fold significantly lower for 177 Lu-DOTA-Fab-PEG 24 -EGF (3.4 6 1.2 %ID/g) than 177 Lu-DOTA-EGF (8.9 6 1.4 %ID/g; P , 0.01) but was not different from 177 Lu-DOTA-trastuzumab Fab (4.5 6 1.4 %ID/g; P 5 0.4). There was lower intestinal uptake for 177 Lu-DOTA-Fab-PEG 24 -EGF than 177 Lu-DOTA-EGF but not compared with 177 Lu-DOTA-trastuzumab Fab.
Radiation Dosimetry Estimates
A comparison of radiation-absorbed doses estimated for the tumor and normal organs in CD1 athymic mice with subcutaneous MDA-MB-231/H2N xenografts and injected with 11.1 (10 mg) of 111 In-DTPA-Fab-PEG 24 -EGF or 177 Lu-DOTA-Fab-PEG 24 -EGF is shown in Table 1 177 Lu-DOTA-Fab-PEG 24 -EGF deposited a 9.3-fold-higher radiation dose in the tumor than 111 In-DTPA-Fab-PEG 24 -EGF.
Normal-Tissue Toxicity Studies
A dose-escalation acute toxicity study was performed to select the dose of 177 Lu-DOTA-Fab-PEG 24 -EGF for radioimmunotherapy studies. There was no significant change in body weight over 14 d for non-tumor-bearing BALB/c mice injected with 3.7-18.5 MBq (10 mg each) of 177 Lu-DOTA-Fab-PEG 24 -EGF compared with normal saline-treated mice, but there was a trend toward decreased body weight for mice receiving 18.5 MBq (Fig. 4 ). There were significantly reduced leukocyte (white blood cell) counts in mice receiving 18.5 MBq of 177 Lu-DOTA-Fab-PEG 24 -EGF compared with saline-treated mice (P 5 0.015; Fig. 5A ) but not for lower doses. Platelet counts were not significantly decreased in mice receiving 177 Lu-DOTA-Fab-PEG 24 -EGF compared with normal saline mice (Fig. 5B) . Erythrocyte (red blood cell) counts, hemoglobin, and hematocrit were significantly lower in mice receiving 18.5 MBq of 177 Lu-DOTA-Fab-PEG 24 -EGF (P 5 0.010, 0.05, and 0.013, respectively; Figs. 5C-5E) than normal saline-treated mice but not at lower doses. There was no significant effect on serum ALT or Cr at any dose of bsRICs (Fig. 6 ), but there was a trend toward higher Cr with increasing dose of 177 Lu-DOTA-Fab-PEG 24 -EGF. On the basis of the overall normal-tissue toxicity profile, a dose of 11.1 MBq (10 mg) was defined as the no observable adverse effect level (NOAEL) and was selected for radioimmunotherapy studies.
Radioimmunotherapy Studies
Radioimmunotherapy studies in mice with MDA-MB-231/H2N (HER2 mod /EGFR mod ) BC xenografts demonstrated strong tumor growth inhibition after a single injection of 11.1 MBq (10 mg) of 177 Lu-DOTA-Fab-PEG 24 -EGF (Fig. 7A) There were no significant differences (P , 0.05) between groups. 
DISCUSSION
We previously reported that 111 In-DTPA-Fab-PEG 24 -EGF bsRICs imaged subcutaneous tumor xenografts in athymic mice that expressed EGFR or HER2 or both receptors (11) . We now extend these findings to radioimmunotherapy by complexing these bsRICs to the b-particle emitter 177 Lu or by exploiting the Auger electron emissions of 111 In. 177 Lu-DOTA-Fab-PEG 24 -EGF bsRICs were constructed by linking trastuzumab Fab fragments to EGF through a PEG 24 spacer and then derivatizing the bsICs with 3.2 6 0.8 DOTA for labeling with 177 Lu (Supplemental Fig. 1 ). DOTA is likely substituted predominantly onto the Fab domain because trastuzumab Fab presents 25 e-amino groups on lysines for reaction with NHS-DOTA (23), whereas EGF contains only 2 lysines and 1 N-terminal amine for DOTA modification or thiolation with Traut's reagent (24) . We previously reported that 111 In-DOTAtrastuzumab Fab exhibited preserved HER2 binding affinity (25) , and 68 Ga-DOTA-EGF was reported to bind with high affinity to EGFR (26) . The binding of 177 Lu-DOTA-trastuzumab Fab or 177 Lu-DOTA-EGF to MDA-MB-231 cells (HER2 low /EGFR mod ) and MDA-MB-231/H2N cells (HER2 mod /EGFR mod ) was inhibited by an excess of trastuzumab Fab or EGF in agreement with the receptor expression of these cells (Supplemental Fig. 2) . Bivalent affibody molecules binding HER2 and EGFR have also been constructed (27) . However, these were not radiolabeled and not studied for tumor imaging or radioimmunotherapy. The dissociation constant for binding of these bispecific affibody molecules to EGFR or HER2 was 35-86 and 6-219 nM, respectively. In competition receptor binding assays with EGF or trastuzumab Fab, we previously measured an effective concentration of 50% for displacement of the binding of 111 In-DTPA-Fab-PEG 24 -EGF to EGFR of 25-36 and 18-24 nM for HER2 (11) . These effective concentration of 50% values approximate the dissociation constant. The specificity of binding of 177 Lu-DOTA-Fab-PEG 24 -EGF to EGFR and HER2 was confirmed by competition with unlabeled EGF or trastuzumab Fab using MDA-MB-231 (HER2 low /EGFR mod ), SK-OV-3 (HER2 high / EGFR low ), MDA-MB-231/H2N (HER2 mod /EGFR mod ), or TrR1 (HER2 mod /EGFR mod ) cells (Fig. 1) . The inability of EGF to compete with the binding of 177 Lu-DOTA-Fab-PEG 24 -EGF to SK-OV-3 cells (HER2 high /EGFR low ) may be due to predominant HER2 binding on these cells due to the 12-fold-greater density of HER2 than EGFR (9.6 · 10 5 vs. 8 · 10 4 receptors/cell, respectively).
Exposure to 177 Lu-DOTA-Fab-PEG 24 -EGF killed all 4 cell types: MDA-MB-231 (HER2 low /EGFR mod ), SK-OV-3 (HER2 high / EGFR low ), MDA-MB-231/H2N (HER2 mod /EGFR mod ), and TrR1 (HER2 mod /EGFR mod ) (Fig. 2) . Monospecific 177 Lu-DOTA-EGF killed MDA-MB-231 cells but was less effective for killing SK-OV-3 cells. Conversely, 177 Lu-DOTA-trastuzumab Fab was more effective for killing SK-OV-3 cells than MDA-MB-231 cells. 111 In-DTPA-Fab-PEG 24 -EGF bsRICs were less cytotoxic than 177 Lu-DOTA-Fab-PEG 24 -EGF (Fig. 2) . Although HER2 contains a putative NLS, the receptor is slowly internalized (28), which may limit the intracellular accumulation of the bsRICs. Moreover, the bsRICs were not modified with exogenous NLS peptides to promote more efficient nuclear importation after HER2-mediated internalization. Nuclear importation amplifies the DNA damage caused by the Auger electrons emitted by 111 In (12) . The longer range (2 mm) b-particles emitted by 177 Lu do not require internalization or nuclear importation of the bsRICs for cytotoxicity. 
